Indirect SPECT Imaging Evaluation for Possible Nose-to-Brain Drug Delivery Using a Compound with Poor Blood–Brain Barrier Permeability in Mice
- Supplementary File 1:
ZIP-Document (ZIP, 50 KiB)
Mizutani, A.; Kobayashi, M.; Ohuchi, M.; Sasaki, K.; Muranaka, Y.; Torikai, Y.; Fukakusa, S.; Suzuki, C.; Nishii, R.; Haruta, S.; Magata, Y.; Kawai, K. Indirect SPECT Imaging Evaluation for Possible Nose-to-Brain Drug Delivery Using a Compound with Poor Blood–Brain Barrier Permeability in Mice. Pharmaceutics 2022, 14, 1026. https://doi.org/10.3390/pharmaceutics14051026
Mizutani A, Kobayashi M, Ohuchi M, Sasaki K, Muranaka Y, Torikai Y, Fukakusa S, Suzuki C, Nishii R, Haruta S, Magata Y, Kawai K. Indirect SPECT Imaging Evaluation for Possible Nose-to-Brain Drug Delivery Using a Compound with Poor Blood–Brain Barrier Permeability in Mice. Pharmaceutics. 2022; 14(5):1026. https://doi.org/10.3390/pharmaceutics14051026
Chicago/Turabian StyleMizutani, Asuka, Masato Kobayashi, Makoto Ohuchi, Keita Sasaki, Yuka Muranaka, Yusuke Torikai, Shota Fukakusa, Chie Suzuki, Ryuichi Nishii, Shunji Haruta, Yasuhiro Magata, and Keiichi Kawai. 2022. "Indirect SPECT Imaging Evaluation for Possible Nose-to-Brain Drug Delivery Using a Compound with Poor Blood–Brain Barrier Permeability in Mice" Pharmaceutics 14, no. 5: 1026. https://doi.org/10.3390/pharmaceutics14051026